Filtered By:
Therapy: Neoadjuvant Therapy

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 12837 results found since Jan 2013.

A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes
Clin Cancer Res. 2021 Jun 9:clincanres.1133.2021. doi: 10.1158/1078-0432.CCR-21-1133. Online ahead of print.ABSTRACTWhile COVID-19 vaccine distribution has addressed vulnerabilities related to age and co-morbidities, there is a need to ensure vaccination of cancer patients receiving experimental and routine treatment, where interruption of treatment by infection is likely to result in inferior outcomes. Among cancer patients, those undergoing neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (Adj chemo) for early breast cancer (EBC) are at particularly high risk for inferior outcomes, in part because optimal timing o...
Source: Clinical Genitourinary Cancer - June 10, 2021 Category: Cancer & Oncology Authors: David A Potter Alexandra Thomas Hope S Rugo Source Type: research

Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials
Abstract Ifosfamide has been used in neoadjuvant chemotherapy since the mid-1980s. Although several studies have been conducted, the results remain controversial. Randomized controlled trials have an improved balance of confounding factors and reliable results. Thus, we performed a meta-analysis based on randomized controlled trials to gather more evidence of the effect of ifosfamide on neoadjuvant chemotherapy for patients with osteosarcoma of the extremity. An electronic search was conducted via the Internet retrieval system to identify eligible trials until September 2014. Odds ratios (ORs) and 95 % confidenc...
Source: Medical Oncology - January 10, 2015 Category: Cancer & Oncology Source Type: research

Small cell carcinoma of the urinary bladder: Changing trends in the current literature.
CONCLUSION: Considering the poor prognosis of the disease, further studies are needed to determine the optimal treatment options and new molecular markers in the way of early diagnosis and favorable outcomes. Prospective, multicenter, randomized studies are required to evaluate the role of neoadjuvant chemotherapy followed either by surgery or radiotherapy. PMID: 26889739 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 19, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

Abstract P5-09-13: The effect of bone pain-specific education vs general chemotherapy side-effect education on reported bone pain in patients (pts) with breast cancer receiving chemotherapy and pegfilgrastim
Conclusions: Our bone pain–specific educational program did not improve perceptions of bone pain reported by this pt population. Bone pain was highest in cycle 1, decreased in cycle 2, and then remained stable.Citation Format: Maxwell CL, Guinigundo AS, Vanni L, Morrow PK, Reiner M, Shih A, Klippel Z, Blanchard E. The effect of bone pain–specific education vs general chemotherapy side-effect education on reported bone pain in patients (pts) with breast cancer receiving chemotherapy and pegfilgrastim. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; Sa...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Maxwell, C., Guinigundo, A., Vanni, L., Morrow, P., Reiner, M., Shih, A., Klippel, Z., Blanchard, E. Tags: Poster Session Abstracts Source Type: research

Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and meta-analysis
AbstractNeoadjuvant treatment in non-metastatic pancreatic cancer (PaC) has the theoretical advantages of downstaging the tumor, sterilizing any present systemic undetectable disease, selecting patients for surgery and administering therapy to each patient. The aim of this systematic review is to analyze the state of the art on neoadjuvant protocols for non-metastatic PaC. A literature search over the last 10  years was conducted, and papers had to be focused on resectable, borderline resectable (BLR) or locally advanced (LA) histo- or cytologically proven PaC; to be prospective studies or prospectively collected database...
Source: Medical Oncology - April 8, 2017 Category: Cancer & Oncology Source Type: research

SABCS 2017 pathology: from bench to bedside
SummaryThe 40th  International San Antonio Breast Cancer Symposium offered a multifaceted platform for the presentation of several innovative therapeutic approaches. The results of these preclinical and clinical studies provided insight into the development of novel therapy concepts from the laboratory bench to t he bedside of breast cancer patients. One main focus of last year’s symposium was the search for synergisms and opportunities for collaboration between basic research scientists and investigators in drug development. Highlights of these topics included preclinical data on selective estrogen recept or covalent ...
Source: Memo - Magazine of European Medical Oncology - August 15, 2018 Category: Cancer & Oncology Source Type: research

The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis
ConclusionsThe taxane-based triplet regimen of TPF is likely the optimal neoadjuvant chemotherapy regimen for LAGC patients.
Source: European Journal of Medical Research - November 9, 2022 Category: Research Source Type: research

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
Biomark Insights. 2022 Feb 22;17:11772719221078774. doi: 10.1177/11772719221078774. eCollection 2022.ABSTRACTTriple negative breast cancer (TNBC) is a high-risk and aggressive malignancy characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR) on the surface of malignant cells, and by the lack of overexpression of human epidermal growth factor 2 (HER2). It has limited therapeutic options compared to other subtypes of breast cancer. There is now a growing body of evidence on the role of immunotherapy in TNBC, however much of the data from clinical trials is conflicting and thus, challenging fo...
Source: Biomarker Insights - February 28, 2022 Category: General Medicine Authors: Sadaf Qureshi Nancy Chan Mridula George Shridar Ganesan Deborah Toppmeyer Coral Omene Source Type: research